Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
NSCLC
Interventions
DRUG

Docetaxel

Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks

DRUG

Bevacizumab

Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks

Trial Locations (5)

Unknown

University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece, Heraklion

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens Athens, Greece, Athens

Medical Oncology Unit NIMTS (Veterans Hospital), Athens

All Listed Sponsors
lead

Hellenic Oncology Research Group

OTHER